InMed Pharmaceuticals Inc. (INM) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 1.49 |
| Open | 1.45 |
| Day High | 1.55 |
| Day Low | 1.45 |
| 52-Week High | 5.5 |
| 52-Week Low | 0.57 |
| Volume | 34,292 |
| Average Volume | 1.66M |
| Market Cap | 2.71M |
| PE | -1.04 |
| EPS | -1.44 |
| Moving Average 50 Days | 1.11 |
| Moving Average 200 Days | 1.33 |
| Change | 0.01 |
InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial
Newsfile
Mar 09, 2026 11:30 AM GMT
Advancing Alzheimer's and Age-Related Macular Degeneration Programs Toward FDA Engagement and IND-Enabling ActivitiesTargeting Initiation of Phase 1 Clinical Trial in Alzheimer's Disease in 2027Vancouver, British Columbia--(Newsfile Corp. - March 9,
InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline
Newsfile
Mar 06, 2026 10:04 PM GMT
Vancouver, British Columbia--(Newsfile Corp. - March 6, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of disease-modifying small molecule drug candidates that ta
InMed Announces Results of 2025 Annual General and Special Meeting
Newsfile
Dec 18, 2025 1:00 AM GMT
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for disea